Ownership and insider activity for Catalyst Pharmaceuticals, Inc. (CPRX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders.
Price
| Price | $31.49 |
| Market Cap | $3.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-15 | Elsbernd Brian | D-Return | 242,501 | $7.6M |
| 2026-07-15 | Elsbernd Brian | D-Return | 132,000 | $612K |
| 2026-07-15 | Elsbernd Brian | D-Return | 200,000 | $684K |
| 2026-07-15 | Elsbernd Brian | D-Return | 135,000 | $954K |
| 2026-07-15 | Elsbernd Brian | D-Return | 69,000 | $1.3M |
| 2026-07-15 | Elsbernd Brian | D-Return | 147,621 | $2.1M |
| 2026-07-15 | Elsbernd Brian | D-Return | 126,704 | $2.7M |
| 2026-07-15 | Elsbernd Brian | D-Return | 98,652 | $2.2M |
| 2026-07-15 | Elsbernd Brian | D-Return | 29,776 | |
| 2026-07-15 | Curran Daniel J. | D-Return | 40,000 | $845K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.9M | $57.5M | $16.6M | $89.5M | $130.2M | $171.4M | $298.4M | $137.6M | $517.6M | $709.2M |
| Short-term Investments | $26.5M | $26.5M | $36.9M | $5.0M | $10.0M | $19.8M | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $10.5M | $6.0M | $6.7M | $10.8M | $53.5M | $65.5M | $128.3M |
| Inventory | 0 | 0 | $56012 | $2.0M | $4.7M | $7.9M | $6.8M | $15.6M | $19.5M | $37.2M |
| Total Current Assets | $41.5M | $85.2M | $55.2M | $111.4M | $159.2M | $210.1M | $320.8M | $219.3M | $623.6M | $894.0M |
| Property, Plant & Equipment | $244204 | $191385 | $245425 | $1.0M | $130000 | $4.0M | $3.6M | $3.7M | $3.6M | $3.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | $32.5M | $194.0M | $156.7M | $131.7M |
| Total Assets | $41.7M | $85.4M | $60.4M | $112.4M | $192.4M | $237.8M | $375.6M | $470.1M | $851.4M | $1.11B |
| Accounts Payable | $933176 | $1.9M | $2.3M | $4.1M | $4.3M | $2.8M | $4.0M | $14.8M | $16.6M | $11.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $437000 |
| Total Current Liabilities | $2.1M | $4.3M | $9.5M | $24.1M | $22.8M | $27.1M | $57.6M | $76.1M | $120.7M | $147.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.4M | $4.4M | $9.7M | $24.7M | $22.8M | $31.0M | $75.2M | $82.2M | $123.8M | $152.5M |
| Retained Earnings | -$108.1M | -$126.6M | -$160.6M | -$128.7M | -$53.7M | -$26.3M | $49.9M | $121.3M | $285.2M | $474.2M |
| Total Equity | $39.3M | $81.0M | $50.8M | $87.6M | $169.6M | $206.8M | $300.4M | $387.9M | $727.6M | $954.3M |
| Total Debt | 0 | 0 | 0 | $948050 | $29000 | $4.2M | $3.9M | $3.6M | $3.2M | $2.8M |
| Net Debt | -$40.4M | -$84.0M | -$53.5M | -$93.6M | -$140.2M | -$187.1M | -$294.5M | -$134.1M | -$514.4M | -$706.4M |
| Working Capital | $39.4M | $80.9M | $45.7M | $87.3M | $136.5M | $183.0M | $263.2M | $143.3M | $502.9M | $746.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 7.10 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 13.94 |
Profitability
| Return on Equity | 23.65% |
| Return on Invested Capital | 19.67% |
| Return on Assets | 19.29% |
| Gross Margin | 82.32% |
| Operating Margin | 44.83% |
| Net Margin | 37.08% |
Related companies: AMLX · AXSM · EXEL · MDGL · TLPH · VKTX · VSTM
Explore sector: Healthcare · Biotechnology
More sections of CPRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks